The transformative potential of plasma phosphorylated tau

The two proteinopathies that define Alzheimer's disease—deposits of aggregated amyloid β and deposits that contain a mixture of three-repeat (3R) and four-repeat (4R) tau isoforms—can be detected in vivo. [...]recently, however, the detection of these biomarkers has been either expensive, in th...

Full description

Saved in:
Bibliographic Details
Published in:Lancet neurology 2020-05, Vol.19 (5), p.373-374
Main Author: Jack, Clifford R
Format: Article
Language:English
Subjects:
Alzheimer's disease
Biomarkers
Clinical trials
Cognitive ability
Dementia
Immunoassay
Isoforms
Neurodegenerative diseases
Older people
Plasma
Primary care
Tau protein
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The two proteinopathies that define Alzheimer's disease—deposits of aggregated amyloid β and deposits that contain a mixture of three-repeat (3R) and four-repeat (4R) tau isoforms—can be detected in vivo. [...]recently, however, the detection of these biomarkers has been either expensive, in the case of PET imaging, or invasive, in the case of CSF sampling, which requires a lumbar puncture. Because plasma p-tau181 seems to indicate occurrence of both amyloid β deposition and tauopathy in Alzheimer's disease, it could be used in trials that target amyloid β or tau or both. To date, a diagnosis of Alzheimer's disease based on biological grounds was impractical in most clinical settings. Because plasma p-tau181 seems to be an indicator of both amyloid β and tauopathy, a single, non-invasive assay could be done to determine whether an individual is on the Alzheimer's disease pathophysiological pathway.
ISSN:1474-4422
1474-4465
DOI:10.1016/S1474-4422(20)30112-5